sildenafil CITRATE NDC 59651-420

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-420Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0420Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-420-11	59651042011	1 BOTTLE in 1 CARTON (59651-420-11) / 112 mL in 1 BOTTLEMarketed from Dec 23, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): sildenafil CITRATE
Generic name (nonproprietary): sildenafil citrate
Active ingredients: Sildenafil citrate — 10 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214773
Marketing start: Dec 23, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 5 Inhibitors (Mechanism)
Identifiers: Product ID 59651-420_39509319-16be-4fc4-a60a-48ea8e9333c6SPL ID 39509319-16be-4fc4-a60a-48ea8e9333c6SPL set ID b60b4fdc-9b78-45e6-8438-8a30f83ed976RxCUI 1307427UNII BW9B0ZE037
Pharmacologic class: Phosphodiesterase 5 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651042011 followed by a unit qualifier and the quantity

Package 59651-0420-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 2, 2026.

Indications (excerpt from the label)

Adults Sildenafil for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14) ] . Pediatric Patients (1 to 17 Years Old) Sildenafil for oral suspension is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ]. Adults Sildenafil is a phosphodiesterase-5 (PDE-5…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)